Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction
نویسندگان
چکیده
منابع مشابه
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
BACKGROUND High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is considered the standard of care for multiple myeloma (MM) patients <65 years. Safety and outcome of ASCT for patients >65 years is currently uncertain, especially since the introduction of novel agents for induction and maintenance therapy. Furthermore, there are no conclusive data available on risk assessmen...
متن کاملConsolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
Advances in therapy in multiple myeloma have resulted in significant improvements in patient outcomes; however, relapse remains problematic. Strategies to improve outcomes following autologous stem cell transplantation (ASCT) include consolidation to intensify therapy and improve depth of response and maintenance therapy to achieve long-term disease control. Immunomodulatory drugs (IMiDs), incl...
متن کاملUpfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
The feasibility and efficacy of high-dose melphalan followed by autologous hematopoietic stem cell transplantation in newly diagnosed elderly patients with multiple myeloma was analyzed prospectively. Fifty-six multiple myeloma patients, aged 65 years or over, from 6 French centers were studied. The induction therapy was bortezomib-based in combination with dexamethasone and either thalidomide,...
متن کاملTailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma.
High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma. This option is usually offered to patients less than 70 years old who have no major comorbidities. Selected older patients and those with mild to moderate organ dysfunction may also be reasonable candidates. An impo...
متن کاملAutologous transplantation for multiple myeloma.
Until now high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) has been considered the standard of care for frontline therapy of multiple myeloma (MM) in younger patients with normal renal function, and MM is currently the first indication of ASCT. However, the introduction of the novel agents thalidomide, bortezomib and lenalidomide is changing the scenario in two w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Oncology
سال: 2018
ISSN: 2374-2437
DOI: 10.1001/jamaoncol.2017.4600